References
- Levine RL, Pardanain A, Tefferi A, Billiland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–683.
- Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
- Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
- Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia and myelofibrosis among 24577 first-degree relatives of 11309 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199–2204.
- Goldin LR, Bjorkholm M, Kristinsson SY, et al. Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. Genome Med 2009;1:55.
- Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446–449.
- Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450–454.
- Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nat Genet 2009;41:455–459.
- Pardanani A, Fridley BL, Lasho TL, et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008;111:2785–2789.
- Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162–2168.
- Pardanani A, Lasho T, Finke CM, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status–clinical correlates in a study of 226 consecutive patients. Leukemia 2009;24:110–114.
- Campbell PJ. Somatic and germline genetics at the JAK2 locus. Nat Genet 2009;41:385–386.
- Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may beat lower risk of thrombotic complications. Blood 1999;93:417–424.
- Lambert JF, Everington T, Linch D, Gale RE. In essential thrombocythemia, multiple JAK20V617F clones are present in most mutant-positive patients. Blood 2009;114:3018–3023.
- Aichberger KJ, Fleischman AG, Deininger MW. Same mutation, different allele. Blood 2009;14:2853–2854.
- Caramazza D, Siragusa, Hanson CA, et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 2010;24:859–860.
- Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010;115:4517–4523.